Compare EBF & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | KALV |
|---|---|---|
| Founded | 1909 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.2M | 551.2M |
| IPO Year | N/A | N/A |
| Metric | EBF | KALV |
|---|---|---|
| Price | $18.62 | $14.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 220.9K | ★ 1.2M |
| Earning Date | 12-22-2025 | 11-10-2025 |
| Dividend Yield | ★ 5.37% | N/A |
| EPS Growth | ★ 5.01 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $388,740,000.00 | $1,426,000.00 |
| Revenue This Year | $0.96 | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.30 | $7.30 |
| 52 Week High | $22.01 | $19.00 |
| Indicator | EBF | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 45.69 |
| Support Level | $17.70 | $15.77 |
| Resistance Level | $18.25 | $19.00 |
| Average True Range (ATR) | 0.40 | 1.09 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 87.83 | 1.92 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.